Venatorx Pharmaceuticals Announces Positive Phase 1 Results for VNRX-7145
Investigational oral beta-lactamase inhibitor VNRX-7145 was well-tolerated with no safety signals up to the highest dose as a single agent
Ceftibuten/VNRX-7145 Combination Phase 1 Study Initiated with Top Line Results Expected Fourth Quarter 2021
Company Plans to Initiate Phase 3 Clinical Trial for Ceftibuten/VNRX-7145 in Second Half 2022